A 5-year-old boy from rural Maharashtra presents with progressive joint pain, stiffness in the knees and ankles, and dark brown discolouration of the sclera and ear cartilage. His urine darkens on standing for several hours. Serum creatinine is normal. Urine chromatography shows elevated homogentisic acid. Genetic testing confirms homozygous mutations in the HGD gene. What is the most appropriate next step in management?

Explanation

## Clinical Context: Alkaptonuria This child presents with the **classic triad of alkaptonuria**: 1. **Ochronosis** — dark brown/black pigmentation of connective tissues (sclera, cartilage, skin) 2. **Arthropathy** — progressive joint pain and stiffness (knees, ankles, spine) 3. **Dark urine on standing** — due to oxidation and polymerization of homogentisic acid Confirmed diagnosis: elevated urinary homogentisic acid + HGD gene mutations. ## Pathophysiology **Key Point:** Alkaptonuria results from deficiency of **homogentisate 1,2-dioxygenase (HGD)**, leading to accumulation of homogentisic acid. This acid oxidizes and polymerizes, depositing dark pigment (alkapton) in connective tissues and causing progressive arthropathy. **High-Yield:** Alkaptonuria is one of the **first described inborn errors of metabolism** (Archibald Garrod, 1902) and follows **autosomal recessive inheritance**. ## Modern Management: Nitisinone + Vitamin C ### Nitisinone (NTBC) **Mechanism:** Inhibits **homogentisate 1,2-dioxygenase** (the enzyme upstream of HGD), blocking the formation of homogentisic acid at source. **Evidence:** - Reduces urinary homogentisic acid by >99% - Slows progression of ochronosis and arthropathy when started early - **FDA-approved** for alkaptonuria (2020) - Most effective if initiated **before age 30** (before extensive pigment deposition) ### Vitamin C (Ascorbic Acid) **Mechanism:** Acts as an **antioxidant**, reducing oxidation and polymerization of homogentisic acid, thereby slowing pigment deposition. **Dose:** Typically 500–1000 mg daily. **Benefit:** Synergistic with nitisinone; reduces ochronosis progression. ### Management Algorithm ```mermaid flowchart TD A[Alkaptonuria confirmed: elevated HGA, HGD mutations]:::outcome --> B{Age and disease stage?}:::decision B -->|Child/young adult, early disease| C[Start nitisinone + high-dose vitamin C]:::action C --> D[Monitor urinary HGA, clinical progression]:::action D --> E[Symptomatic management: NSAIDs for pain]:::action E --> F[Long-term rheumatology/nephrology follow-up]:::action B -->|Adult, advanced arthropathy| G[Nitisinone + vitamin C + NSAIDs]:::action G --> H[Consider orthopaedic intervention if severe]:::action A --> I{Renal involvement?}:::decision I -->|Proteinuria/declining GFR| J[ACE inhibitor for renal protection]:::action I -->|Normal renal function| K[Routine monitoring]:::action ``` ## Why This Answer is Correct **Nitisinone + vitamin C** is the **disease-modifying therapy** for alkaptonuria. At age 5, this child is in the optimal window for intervention — before extensive ochronosis and arthropathy have developed. Early treatment can slow or halt disease progression. ## Comparison: Alkaptonuria vs. Other Aminoacidurias | Feature | Alkaptonuria | PKU | MSUD | | --- | --- | --- | --- | | **Enzyme defect** | Homogentisate oxidase | Phenylalanine hydroxylase | BCAA dehydrogenase | | **Neonatal presentation** | None (asymptomatic) | Musty odour, poor feeding | Seizures, encephalopathy | | **Age of clinical onset** | Adulthood (30–40 yrs) | Weeks–months (if untreated) | Days–weeks | | **Primary manifestation** | Ochronosis, arthropathy | Intellectual disability | Neurological crisis | | **First-line treatment** | Nitisinone + vitamin C | Dietary restriction | BCAA-free nutrition, ICU | | **Inheritance** | Autosomal recessive | Autosomal recessive | Autosomal recessive | **Clinical Pearl:** Alkaptonuria is often **asymptomatic in childhood** — the dark urine and ochronosis may go unnoticed. However, once diagnosed, **early intervention with nitisinone is crucial** to prevent arthropathy and renal complications (proteinuria can develop in adulthood).